Q&A: HIV ART Safety Part 2
Questions Answered on ART Safety and Tolerability in Pregnant People and Transgender Individuals

Released: February 23, 2023

Expiration: February 22, 2024

Jill Blumenthal
Jill Blumenthal, MD, MAS
William R. Short
William R. Short, MD, MPH, FIDSA

Activity

Progress
1
Course Completed

In this episode, Jill Blumenthal, MD, MAS, and William R. Short, MD, MPH, AAHIVS, address key considerations when evaluating ART safety and tolerability in pregnant people, those trying to conceive, and transgender individuals, such as:

  • Approaching patients trying to conceive on nonpreferred ART regimens (eg, 2-drug regimens like LA CAB and RPV)
  • Optimizing the use of the Antiretroviral Pregnancy Registry
  • Addressing unique barriers to ARV adherence in transgender individuals with HIV (eg, drug formulation considerations for ARV medications and gender-affirming hormone therapy, sperm banking or egg harvesting, drug coverage considerations)